FDA Clears Zepbound as New Option for Obesity Treatment
FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management
Read More →
Fda Regulation
FDA Warns of Adverse Events Linked to Unapproved Compounded Versions of GLP-1 Drugs
The Food and Drug Administration has updated its safety communications regarding compounded semaglutide. Officials cite reports of patients experiencing nausea, vomiting,…
More stories
What Primary Literature Shows About Plant-Based Eating Patterns and Prostate Cancer Risk in Men
Cohort data summarized by the National Cancer Institute show that men following plant-based eating patterns had lower…
Read More →FDA Clarifies Which Digital Wellness Tools Fall Under Medical Device Regulation
The FDA has spelled out more details on its oversight of digital health products. Its risk-based framework looks at…
Read More →FDA Outlines Predetermined Change Control Plans for AI/ML-Based Cardiac Devices
FDA Updates Regulatory Expectations for AI-Enabled Cardiovascular Monitoring Devices
Read More →FDA Clears First OTC CGM Device for Diabetes Management and Prevention
FDA Clears First Over-the-Counter Continuous Glucose Monitor
Read More →Pooled Cohort and Trial Data Link Resistance Exercise to Higher Bone Density in Men Over 50
Resistance Training Associated With Modest BMD Gains in Middle-Aged and Older Men
Read More →What Multiple Longitudinal Studies Show About Sleep and Hormonal Health in Men
Cohort Findings Link Short Sleep to Lower Testosterone and Cardiometabolic Risks in Middle-Aged Men
Read More →FDA Requires Updated Warnings on Cardiovascular Risks for Certain Prostate Cancer Treatments
FDA Updates Labeling for GnRH Agonists With New Warnings on Diabetes and Cardiovascular Risks
Read More →